

Remarks


In response to the Examiner's restriction of claims 1-18 into two groups: claims 1-17 drawn to products as Group I and claim 18 drawn to methods as Group II, Applicants herein elect Group I and more particularly elect Example 237 found on page 226 of the instant application. Applicants submit that the scope of claims 1-17 was drawn to Group IV arising from a first restriction requirement issued during the prosecution of the parent case (USSN 10/044,183) under Examiner Truong. Thus, no further amendments to the scope of Claims 1-17 are required.

Applicants have also cancelled claim 18 directed to methods of treatment and pursuant to MPEP 809.04 regarding rejoinder of claims, reserve the right to reintroduce method of use claims which include all the limitations of any elected composition claims (linking claims) that are deemed to be allowable. Upon said rejoinder, Applicants elect "headache" as the method of treatment. Applicants also reserve the right to file divisional application(s) on any non-elected subject matter.

In light of the amendments and remarks herein, Applicants respectfully request the Examiner to enter said amendments and respectfully submit that the application is in condition for examination. The Commissioner is authorized to withdraw an fees from Deposit Account 19-3880.

Respectfully submitted,

Dated: August 16, 2005



Shah R. Makujina  
Attorney for Applicant  
Registration No. 41,174

Bristol-Myers Squibb Company  
P.O. Box 4000  
Princeton, NJ 08543-4000

Tel: (203) 677-7268  
Facsimile: (203) 677-6900